LimmaTech Biologics AG

Swiss clinical-stage biopharmaceutical company developing next-generation vaccines against antimicrobial-resistant bacterial pathogens such as S. aureus, N. gonorrhoeae and C. trachomatis. Lead candidate LTB-SA7 is in Phase 1. Acquired by Eli Lilly for up to $780 million.